Myriad quizzed by Supreme Court justices
In a landmark case with sweeping repercussions for medical research that's being closely watched around the globe, the US Supreme Court on Monday heard oral arguments on the patent eligibility of human genes
Association for Molecular Pathology v Myriad
Genetics hinges on whether the building blocks of life
that form the human genome are also intellectual property.
A coalition of plaintiffs that includes researchers,
patients, and breast cancer and women's health groups argue
that genetic material is a "product of nature" that is
ineligible for patents.
Utah-based Myriad, whose supporters include the
Biotechnology Industry Organization (BIO) and the Coalition for
21st Century Medicine, maintains that genetic material removed
from the body through "invented" methods can be patented
because it is no longer naturally occurring.
The lawsuit was brought by the ACLU and the Public Patent
Foundation, a non-profit legal group affiliated with the
Benjamin N Cardozo School of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of one week’s FREE access
and become a Managing IP member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain 7 days FREE access when you register now.